TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32393358

Group type: EXPERIMENTAL
Intervention: In-depth phenotyping and omics assessments
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Validated paradigms (e.g., fear conditioning, reward anticipation, imaging stress test, social reward learning task)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Multilevel assessments (genetic, molecular, cellular, physiological, neuroimaging, neurocognitive, psychophysiological, psychometric)
Number of subjects: 1500
Study: 32394292

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants (OACs) including dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban
Number of subjects: 62888
Study: 32394403

Group type: EXPERIMENTAL
Intervention: Abnormal perfusion (defined as a summed stress score (SSS) ≥ 4)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Inability to exercise > 4 METs
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Combined assessment of functional status and myocardial perfusion
Number of subjects: 404

Group type: COMPARATOR
Intervention: Normal perfusion
Number of subjects: 404
Study: 32394598

Group type: EXPERIMENTAL
Intervention: CAA-related ICH patients
Number of subjects: 36

Group type: COMPARATOR
Intervention: Controls with deep ICH
Number of subjects: 36
Study: 32395294

Group type: EXPERIMENTAL
Intervention: SV-VATS (non-intubated spontaneous ventilation)
Number of subjects: 316

Group type: COMPARATOR
Intervention: MV-VATS (intubated mechanical ventilation)
Number of subjects: 316
Study: 32395337

Group type: EXPERIMENTAL
Intervention: Atenolol 50 or 100 mg
Number of subjects: 25
Study: 32395501

Group type: EXPERIMENTAL
Intervention: Periprocedural aggressive hydration
Number of subjects: 560

Group type: COMPARATOR
Intervention: General hydration
Number of subjects: 560
Study: 32395547

Group type: EXPERIMENTAL
Intervention: Extubation success within 48 hours following endotracheal tube removal
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Various time-frames for extubation success rate (within 96 hours, >96 hours after extubation)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Validation of existing prediction scores for successful extubation
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Current practices of extubation and tracheostomy
Number of subjects: 1500
Study: 32395709

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) administered via implanted intra-cerebroventricular delivery system at a maximum dose of 160 mg/day
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) administered via implanted intra-cerebroventricular delivery system
Number of subjects: 5
Study: 32396014

Group type: EXPERIMENTAL
Intervention: Nivolumab plus 5-FU+CDDP (cisplatin and 5-fluorouracil)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One prior administration of nivolumab and the cohort A regimen (5-FU+CDDP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nivolumab plus docetaxel+ CF (cisplatin and 5-fluorouracil)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One prior administration of nivolumab and the cohort C regimen (docetaxel+ CF)
Number of subjects: 0
Study: 32396475

Group type: EXPERIMENTAL
Intervention: Use of protective barrier during sexual activity
Number of subjects: 141
Study: 32396615

Group type: EXPERIMENTAL
Intervention: CWP232291 (CWP291) administered IV daily for 7 days every 21 days
Number of subjects: 69
Study: 32397857

Group type: EXPERIMENTAL
Intervention: ABTL0812
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacological manipulation to increase cellular dihydroceramides or incubation with exogenous dihydroceramides
Number of subjects: 0
Study: 32398128

Group type: EXPERIMENTAL
Intervention: Electrodermal activity (EDA) assessment during exposure therapy
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Subjective Units of Distress Scale (SUDS) during exposure therapy
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Trait physiological arousal survey
Number of subjects: 34
Study: 32398156

Group type: EXPERIMENTAL
Intervention: Chamas participation (group-based health education and microfinance program)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Control (standard of care)
Number of subjects: 326
Study: 32398308

Group type: EXPERIMENTAL
Intervention: Rifampicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 0
Study: 32398351

Group type: EXPERIMENTAL
Intervention: Increased glucose variability (GV) measured as standard deviation (SD) and coefficient of variation (CV) during the last day of hospitalization.
Number of subjects: 1042150
Study: 32398478

Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg subcutaneously
Number of subjects: 5
Study: 32398792

Group type: EXPERIMENTAL
Intervention: elotuzumab therapy
Number of subjects: 0
Study: 32399045

Group type: EXPERIMENTAL
Intervention: Bone Marrow Concentrate (BMC) with Platelet-Rich Plasma (PRP) and Platelet Lysate (PL) injections
Number of subjects: 25

Group type: COMPARATOR
Intervention: Exercise therapy
Number of subjects: 25
Study: 32399187

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32399214

Group type: EXPERIMENTAL
Intervention: shRNA-IL6-modified anti-CD19 CAR-T therapy (ssCAR-T-19)
Number of subjects: 1
Study: 32399254

Group type: EXPERIMENTAL
Intervention: Mini-AFTERc intervention delivered by specialist breast cancer nurses (SBCNs) over the telephone, structured 30-min counselling intervention.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study: 32399263

Group type: EXPERIMENTAL
Intervention: MVT-5873 (a cytotoxic monoclonal antibody targeting CA 19-9) administered as a single dose three days before resection and four post-operative infusions.
Number of subjects: 0
Study: 32399595

Group type: EXPERIMENTAL
Intervention: Intra- and/or postoperative blood transfusion(s)
Number of subjects: 1546

Group type: EXPERIMENTAL
Intervention: American Society of Anesthesiologists class III vs I-II
Number of subjects: 1546

Group type: EXPERIMENTAL
Intervention: Extra- vs intra-corporeal anastomosis
Number of subjects: 1546

Group type: EXPERIMENTAL
Intervention: Female vs male gender
Number of subjects: 1546

Group type: EXPERIMENTAL
Intervention: Length of the procedure
Number of subjects: 1546

Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 1546
Study: 32399622

Group type: EXPERIMENTAL
Intervention: Newly developed PET radioligand
Number of subjects: 10

Group type: COMPARATOR
Intervention: One- and unconstrained two-tissue compartment models, Logan graphical analysis
Number of subjects: 10
Study: 32399752

Group type: EXPERIMENTAL
Intervention: Bayesian penalized likelihood (BPL) reconstruction algorithm
Number of subjects: 20

Group type: COMPARATOR
Intervention: OSEM reconstruction
Number of subjects: 20
Study: 32399958

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg every 3 weeks until loss of clinical benefit or unacceptable toxicity
Number of subjects: 25
Study: 32401215

Group type: EXPERIMENTAL
Intervention: TV-AssistDem (TeleVision-based ASSistive Integrated Service)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 93
Study: 32401225

Group type: EXPERIMENTAL
Intervention: Social media intervention with financial incentives
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: Social media intervention without financial incentives (SMI)
Number of subjects: 955

Group type: COMPARATOR
Intervention: Attention placebo control (entertaining social media content)
Number of subjects: 955
Study: 32401293

Group type: EXPERIMENTAL
Intervention: Preoperative SURPASS checklist
Number of subjects: 9009

Group type: EXPERIMENTAL
Intervention: Postoperative SURPASS checklist
Number of subjects: 9009

Group type: COMPARATOR
Intervention: Parallel control units
Number of subjects: 9009

Group type: COMPARATOR
Intervention: Control group (WHO SSC only)
Number of subjects: 9009
Study: 32401302

Group type: EXPERIMENTAL
Intervention: Overweight/Obese (OW) mothers' human milk
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Infants of OW mothers
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Human milk insulin and leptin
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Macronutrients in human milk
Number of subjects: 174
Study: 32401592

Group type: EXPERIMENTAL
Intervention: multi-component intervention
Number of subjects: 0
Study: 32401707

Group type: EXPERIMENTAL
Intervention: 0.5 mL/kg 0.25% bupivacaine (Group B)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 0.5 mL/kg 0.25% bupivacaine + 3 mg/kg 1% lidocaine (Group BL)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Intra-operative intravenous fentanyl use
Number of subjects: 86
Study: 32401731

Group type: EXPERIMENTAL
Intervention: Monitoring of resident movements using a wearable sensor and observation of repositioning events.
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Braden Pressure Ulcer Risk Assessment conducted weekly.
Number of subjects: 2
Study: 32401744

Group type: EXPERIMENTAL
Intervention: Revefenacin (LAMA) and Formoterol Fumarate (LABA) inhalation solution admixture
Number of subjects: 0
Study: 32402161

Group type: EXPERIMENTAL
Intervention: Lactin-V
Number of subjects: 228

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study: 32402922

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (surgery)
Number of subjects: 97
Study: 32403243

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for six weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control condition (no aerobic exercise)
Number of subjects: 25
Study: 32403379

Group type: EXPERIMENTAL
Intervention: Liposomal anthralin gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethosomal anthralin gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32404003

Group type: EXPERIMENTAL
Intervention: Transference work in psychodynamic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 32404008

Group type: EXPERIMENTAL
Intervention: Hypercaloric diet
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (n=5)
Number of subjects: 15
Study: 32404091

Group type: EXPERIMENTAL
Intervention: Surgical treatment of pancreatic metastases
Number of subjects: 26
Study: 32404437

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin at 75-100 mg/kg/day divided doses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular gentamicin
Number of subjects: 0
Study: 32404502

Group type: EXPERIMENTAL
Intervention: Subjects in northern China
Number of subjects: 119

Group type: COMPARATOR
Intervention: Subjects in southern China
Number of subjects: 119
Study: 32404868

Group type: EXPERIMENTAL
Intervention: Radium-223 plus abiraterone/prednisone
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Radium-223 plus enzalutamide
Number of subjects: 625

Group type: COMPARATOR
Intervention: Radium-223
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Radium-223 with bone health agents (BHAs)
Number of subjects: 625
Study: 32405431

Group type: EXPERIMENTAL
Intervention: Phosphorus supplementation (400 mg) with glucose
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (glucose without phosphorus)
Number of subjects: 12
Study: 32405623

Group type: EXPERIMENTAL
Intervention: 600 mg albendazole (PSAC)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: 600 mg albendazole (SAC)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: 400 mg albendazole (Adults)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Any adverse event
Number of subjects: 333
Study: 32406487

Group type: EXPERIMENTAL
Intervention: PrOD (paritaprevir-ritonavir-ombitasvir plus dasabuvir) for 12 weeks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: PrOD (paritaprevir-ritonavir-ombitasvir plus dasabuvir) for 24 weeks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: PrOD (paritaprevir-ritonavir-ombitasvir plus dasabuvir)
Number of subjects: 45
Study: 32406862

Group type: EXPERIMENTAL
Intervention: VoiceSense digital voice analysis tool analyzing 200 specific speech parameters
Number of subjects: 254

Group type: COMPARATOR
Intervention: Psychological questionnaires (SCL-90, PHQ, Big 5 Test)
Number of subjects: 254
Study: 32406919

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory dietary changes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pro-inflammatory dietary changes
Number of subjects: 0
Study: 32406978

Group type: EXPERIMENTAL
Intervention: Cryptogenic stroke patients
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lowest tertile of cryptogenic stroke patients
Number of subjects: 60

Group type: COMPARATOR
Intervention: Stroke-free controls
Number of subjects: 60
Study: 32407157

Group type: EXPERIMENTAL
Intervention: Invasive Tracheobronchial Aspergillosis treatment; specific intervention details not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group; specific details not available
Number of subjects: 0
Study: 32407247

Group type: EXPERIMENTAL
Intervention: Motor skill training
Number of subjects: 0
Study: 32407400

Group type: EXPERIMENTAL
Intervention: Maternal genetic locus ITPR1 (rs746039 [G])
Number of subjects: 1849

Group type: EXPERIMENTAL
Intervention: Decreased placental expression of ITPR1
Number of subjects: 1849

Group type: EXPERIMENTAL
Intervention: Genetic risk score composed of known maternal SNPs
Number of subjects: 1849
Study: 32407591

Group type: EXPERIMENTAL
Intervention: Guselkumab 200 mg (subcutaneous)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Probe cocktail (midazolam, S-warfarin, omeprazole, dextromethorphan, caffeine)
Number of subjects: 14
Study: 32407672

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32407888

Group type: EXPERIMENTAL
Intervention: Mexican-born parents
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Parent depression
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Instrumental Support
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Residential years in the United States
Number of subjects: 165
Study: 32408111

Group type: EXPERIMENTAL
Intervention: Dolutegravir plus lamivudine
Number of subjects: 41
Study: 32408387

Group type: EXPERIMENTAL
Intervention: Silicone oil
Number of subjects: 601

Group type: COMPARATOR
Intervention: Sulfur hexafluoride (SF6)
Number of subjects: 601
Study: 32408397

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 38
Study: 32408769

Group type: EXPERIMENTAL
Intervention: Use of electronic health records in the STRIDE trial
Number of subjects: 0
Study: 32408828

Group type: EXPERIMENTAL
Intervention: Echocardiographic parameters for assessing MR severity
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: PISA-based regurgitant volume, PISA-based effective regurgitant orifice area, and vena contracta
Number of subjects: 159
Study: 32408984

Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor T-Cells (CAR-T)
Number of subjects: 0
Study: 32409206

Group type: EXPERIMENTAL
Intervention: Plasma OPN levels at day 1
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: Reduction of OPN levels during the first 7 days
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: Plasma OPN at day 1
Number of subjects: 957
Study: 32410049

Group type: EXPERIMENTAL
Intervention: Transdiagnostic adherence counseling and cognitive behavioral therapy
Number of subjects: 27
Study: 32410080

Group type: EXPERIMENTAL
Intervention: Capmatinib 400 mg twice daily plus cetuximab (weekly intravenous at approved dose)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Capmatinib (150, 300, and 400 mg) plus cetuximab
Number of subjects: 13
Study: 32410147

Group type: EXPERIMENTAL
Intervention: Alemtuzumab 12 mg/day on 5 consecutive days at baseline and on 3 consecutive days 12 months later
Number of subjects: 811
Study: 32410305

Group type: EXPERIMENTAL
Intervention: Parents with elevated depressive symptoms
Number of subjects: 128

Group type: COMPARATOR
Intervention: Parents without depressive symptoms
Number of subjects: 128
Study: 32410526

Group type: EXPERIMENTAL
Intervention: Culprit vessels
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Non-culprit vessels
Number of subjects: 115
Study: 32410532

Group type: EXPERIMENTAL
Intervention: Caraway extract, consumed during a ninety days clinical trial.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ANFIS-PSO analysis method.
Number of subjects: 0
Study: 32410617

Group type: EXPERIMENTAL
Intervention: Model-based personalized robot-aided rehabilitation therapy
Number of subjects: 19
Study: 32410668

Group type: EXPERIMENTAL
Intervention: Interprofessional training unit (intervention group)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Conventionally organized ward (comparison group)
Number of subjects: 252
Study: 32410670

Group type: EXPERIMENTAL
Intervention: Dialectical Behaviour Therapy (DBT) implementation
Number of subjects: 82
Study: 32411082

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 32411374

Group type: EXPERIMENTAL
Intervention: 16-week supervised heavy resistance training program with weekly undulating periodization
Number of subjects: 25
Study: 32411381

Group type: EXPERIMENTAL
Intervention: Behavioral activation group therapy (BA) in addition to usual care
Number of subjects: 20

Group type: COMPARATOR
Intervention: Support group in addition to usual care
Number of subjects: 20
Study: 32411388

Group type: COMPARATOR
Intervention: PPV without ILM peeling (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PPV with ILM peeling (Group B)
Number of subjects: 60
Study: 32411431

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab injections
Number of subjects: 26
Study: 32411640

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32411717

Group type: EXPERIMENTAL
Intervention: Intravenous Cyclophosphamide, dosage and duration not available
Number of subjects: 0
Study: 32411845

Group type: EXPERIMENTAL
Intervention: 30-minute passive exposure to e-cigarette emissions
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control session (no exposure)
Number of subjects: 40
Study: 32411946

Group type: EXPERIMENTAL
Intervention: PrEP demand creation video
Number of subjects: 320

Group type: COMPARATOR
Intervention: Having a primary partner
Number of subjects: 320

Group type: COMPARATOR
Intervention: Being in a sexual partnership for <6 months
Number of subjects: 320
Study: 32412142

Group type: EXPERIMENTAL
Intervention: Vitamin D sufficient group (serum 25OHD ≥ 20 ng/mL)
Number of subjects: 1308

Group type: EXPERIMENTAL
Intervention: Vitamin D insufficient group (serum 25OHD 10-20 ng/mL)
Number of subjects: 1308

Group type: EXPERIMENTAL
Intervention: Vitamin D deficient group (serum 25OHD ≤ 10 ng/mL)
Number of subjects: 1308

Group type: COMPARATOR
Intervention: Serum 25OHD < 20 ng/mL
Number of subjects: 1308

Group type: EXPERIMENTAL
Intervention: Serum 25OHD ≥ 20 ng/mL
Number of subjects: 1308
Study: 32412989

Group type: EXPERIMENTAL
Intervention: TFA-1 sensor
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Finger sensor
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: ΔVpeak
Number of subjects: 37
Study: 32413298

Group type: EXPERIMENTAL
Intervention: Dynamic stimulation of visual cortex using a visual cortical prosthesis (VCP) to trace shapes on the surface of visual cortex.
Number of subjects: 0
Study: 32414330

Group type: EXPERIMENTAL
Intervention: Bioresorbable polymer drug-eluting stent (BP-DES)
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Durable polymer drug-eluting stent (DP-DES)
Number of subjects: 1400
Study: 32414346

Group type: EXPERIMENTAL
Intervention: Ready-to-use food (RUF) provided according to WHO prescription weight- and age-bands for a maximum of 9-12 months.
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Ready-to-use food (RUF) provided according to WHO prescription weight- and age-bands.
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Factors associated with sub-optimal RUF intake at week 2.
Number of subjects: 173
Study: 32414362

Group type: EXPERIMENTAL
Intervention: Shear wave elastography (SWE) technology
Number of subjects: 0
Study: 32414392

Group type: EXPERIMENTAL
Intervention: Haplo-SCT
Number of subjects: 131

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 131
Study: 32414527

Group type: EXPERIMENTAL
Intervention: Tack Endovascular System
Number of subjects: 201
Study: 32414772

Group type: EXPERIMENTAL
Intervention: Early recognition and appropriate treatment
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Public awareness on dangerous allergic reactions
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Contemporary preventative medicine and efficient therapeutic protocols
Number of subjects: 1
Study: 32414827

Group type: EXPERIMENTAL
Intervention: Centralised Chronic Medication Dispensing and Distribution (CCMDD) programme
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard clinic-based ART provision
Number of subjects: 55
Study: 32414848

Group type: EXPERIMENTAL
Intervention: Entospletinib
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Entospletinib + Vincristine chemotherapy
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Entospletinib + Selumetinib
Number of subjects: 12
Study: 32414850

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP)
Number of subjects: 31
Study: 32414862

Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg intravenously every 2 weeks
Number of subjects: 88
Study: 32415575

Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 302

Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 302
Study: 32415586

Group type: EXPERIMENTAL
Intervention: Automated quantification of high signal intensity volumes using ultrashort echo-time MRI (%MR-HSV)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Automated quantification of low signal intensity volumes using ultrashort echo-time MRI (%MR-LSV)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Automated MR metrics
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: %MR-TSV
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Variation of %MR-HSV
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Reproducibility of automated quantification
Number of subjects: 30
Study: 32415705

Group type: COMPARATOR
Intervention: Direct oral anticoagulants (DOACs) - high-dose
Number of subjects: 47469

Group type: COMPARATOR
Intervention: Direct oral anticoagulants (DOACs) - low-dose
Number of subjects: 47469

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKAs)
Number of subjects: 47469
Study: 32415708

Group type: EXPERIMENTAL
Intervention: HSK3486 (0.4 mg/kg)
Number of subjects: 0
Study: 32415771

Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 0